ReviewTranslational cancer research2026
Emerging role of human epidermal growth factor 2-low status in the prognosis and management of triple-negative breast cancer: a narrative review.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Triple-negative breast cancer (TNBC) remains one of the most aggressive and therapeutically challenging breast cancer subtypes. Lack of targeted therapies in TNBC mandates identification of novel molecular and therapeutic vulnerabilities. Human epidermal growth factor 2 (HER2)-low breast cancer, defined by immunohistochemistry (IHC) score 1+ or 2+ with negative Methods: We queried the PubMed database, Google Scholar and other databases for studies published in English (up to April 2026) and available online, using search terms (such as TNBC, breast cancer, HER2-low, HER2-ultralow, trastuzumab deruxtecan, T-DXd, T-DM1), and selected publications based on their relevance to the topic. We also hand-searched reference lists of relevant papers to provide the most updated and comprehensive review of the topic, and utilized "ClinicalTrials.gov" to identify studies exploring anti-HER2 directed treatments in HER2-low and HER2-ultralow breast cancers, with an emphasis on TNBC. Key Content and Findings: HER2-low TNBC represents a relatively large proportion of TNBC cases, and is gaining recognition as a distinct therapeutic and biological subtype, affecting clinical management. In HER2-low TNBC patients, utilization of anti-HER2 targeted therapies, similar to those in HER2-positive breast cancer patients, has been recently shown to offer clinical advantages. Namely, antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd), confers survival benefits in patients with HER2-low breast cancer, including HER2-low TNBC patients with metastatic disease. Ongoing clinical trials investigate T-DXd in various clinical settings as a monotherapy or in combination with chemotherapeutic, immunotherapeutic and targeted drugs in patients with hormone (HR) receptor-negative and HER2-low expressing breast cancer. New HER2-directed ADCs are also being developed, with several being investigated in clinical trials. Conclusions: The development of new HER2-directed treatments is revolutionizing the management of TNBC patients, and mandates further research to better detect and target clinically meaningful HER2-positive signals. This manuscript provides analysis and synthesis of current literature to potentially guide future research and clinical efforts directed at improving outcomes of patients with TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.